Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Elevated blood pressure is the most important risk factor for cardiovascular disease. Numerous clinical practice guidelines for blood pressure coexist, emanating from European,1,2 North American,3 ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

Patients aged 65 years and older who use acetaminophen demonstrate greater risks for serious complications, including ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...

Investing.com -- Shares of Keros Therapeutics (NASDAQ:KROS) tumbled 17% after the company announced a voluntary halt on all dosing in the TROPOS trial, which is evaluating cibotercept (KER-012) in ...

High blood pressure can damage your arteries and put extra strain on your heart, potentially leading to a heart attack, ...

RANGPUR, Jan 15, 2025 (BSS) - Vice-chancellor of Begum Rokeya University, Rangpur (BRUR) Professor Dr Md Showkat Ali has said ...

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

With over 1 108 patients diagnosed with cancer each year, the designation of Manzini Government Hospital as a comprehensive cancer treatment centre brings hope to many. Prime Minister (PM) Russell ...

Heart disease and breast cancer are two of the most significant health threats facing Black women today. Here's ...